Prodo Laboratories

Executive Summary

Prodo Laboratories is a specialized provider of high-quality human islets for diabetes research, catering to academic and pharmaceutical clients. Founded in 2006 and based in Irvine, California, the company differentiates itself through proprietary cGMP media that enhances islet recovery, functionality, and viability. Its services include isolating islets from normal and Type 2 diabetic human pancreases, as well as contract isolations from animal models like mice and rats. This niche positioning supports preclinical studies and drug discovery, though the market is limited and competitive. As a private company with no disclosed funding or revenue, Prodo's growth trajectory is modest, relying on repeat business and word-of-mouth within the research community. The lack of public catalysts or recent news suggests a steady, unexciting operation. The conviction score reflects a low-risk but low-upside profile, with limited visibility into near-term value drivers.

Upcoming Catalysts (preview)

• TBDExpansion of animal islet contract services (e.g., larger mammals)40% success
• TBDPartnership or supply agreement with a major diabetes research consortium30% success
• TBDAdoption of proprietary cGMP media by external islet isolation facilities20% success